MEK inhibitors: a promising targeted therapy for cardiovascular disease

Frontiers in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: 11

Published: July 1, 2024

Cardiovascular disease (CVD) represents the leading cause of mortality and disability all over world. Identifying new targeted therapeutic approaches has become a priority biomedical research to improve patient outcomes quality life. The RAS-RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase) pathway is gaining growing interest as potential signaling cascade implicated in pathogenesis CVD. This pivotal regulating cellular processes like proliferation, growth, migration, differentiation, survival, which are vital maintaining cardiovascular homeostasis. In addition, ERK involved controlling angiogenesis, vascular tone, myocardial contractility, oxidative stress. Dysregulation this been linked cell dysfunction cardiac pathological remodeling, contribute onset progression Recent ongoing provided insights into interventions targeting RAS-RAF-MEK-ERK pathologies. Preclinical studies have demonstrated efficacy therapy with MEK inhibitors (MEKI) attenuating activation mitigating CVD animal models. article, we first describe how contributes preserving health. We then summarize current knowledge roles played by development disorders, including atherosclerosis, infarction, hypertrophy, heart failure, aortic aneurysm. finally report novel strategies for these CVDs encompassing MEKI discuss advantages, challenges, future developments therapeutics.

Language: Английский

Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity

Current Oncology Reports, Journal Year: 2024, Volume and Issue: 26(11), P. 1431 - 1441

Published: Sept. 24, 2024

Language: Английский